CEE Conversion Energy Enterprises
Home | About Us | Management | | Contact

Wound Healing Application

Approximately 2 million patients each year develop hospital-acquired (nosocomial) infections, with surgical wound infections being the most common. It has also been reported that 1 of every 24 (4.1%) patients who have inpatient surgery in the US develops a wound infection. These infections cause as many as 100,000 deaths per year, and incur costs as high as 3.5 billion dollars annually. In the United States, wound infections increase costs of hospitalization by more than 3,000 dollars per patient. While the conventional treatment of infections includes both focused and broad-spectrum antibiotics, there has been an alarming trend of microbial resistance to these agents. This resistance is believed to occur as a result of chromosomal mutation, inductive expression of latent chromosomal genes, or exchange of genetic material via transformation, bacteriophage transduction, or plasmid conjugation.

Our Solution
CEE is currently developing novel photo activated collagen dressings that exhibit bactericidal effects with minimal toxicity and low susceptibility to microbial resistance. These dressings can greatly enhance the arsenal of antimicrobial agents for the management of wound infections. In-vitro and in-vivo experiments have successfully demonstrated how light activated dressings significantly inhibit bacterial growth in-vitro, including biofilm scenarios. In addition, the bacterial growth inhibition is robust; bacterial loads in-vivo for infected incision, wound abscess and pressure ulcer models have beed found to be significantly reduced. Similar results were obtained for Staphylococcus aureus, MRSA, Pseudomonas aeruginosa and Escherichia coli infections.

CEE's next step is to further refine our photo activated antimicrobial collagen technology as a wound treatment to encourage wound closure and healing, and reduce acute and chronic wound infections. Our studies will provide important preclinical results designed to optimize materials for human clinical studies and FDA approval